In the other open label trial, CREATE-X, reported by the Japanese Breast Cancer Research Group (JBCRG) in 2015, also called JBCRG-04, all 910 eligible patients had HER-2-negative stage I to IIIB BC and had residual disease in the breast or lymph nodes after neoadjuvant chemotherapy. Here, ERBB2 is linked to breast cancer.